

Press Coverage | January 10, 2023

JPM23: Vaccine Developers as Dealmakers, Gilead's Trial Tea Leaves and Building Platform Companies

RELATED PROFESSIONALS

Christopher S. Miller

Troutman Pepper Partner Chris Miller was quoted in the January 10, 2023 *BioPharma Dive* article, “[JPM23: Vaccine Developers as Dealmakers, Gilead's Trial Tea Leaves and Building Platform Companies.](#)”

Across the industry, biotechs are having difficulty going public. Startups are struggling to bring new investors in and to raise new rounds at higher values, said Chris Miller, a partner and leader of Troutman Pepper's emerging companies and venture capital team.

RELATED INDUSTRIES + PRACTICES

- [Emerging Companies + Venture Capital](#)